Key Drivers
- High profitability
- Strong FCF
- Large intangibles
AIAI Summary
Danaher's thesis shifts from a “durable healthcare compounder” to a high‑cash, event‑driven trade: strong FCF and margin durability underpin upside, but the Masimo acquisition, heavy intangibles, and stretched valuation concentrate near‑term litigation and integration risk that can quickly overwhelm returns. Actionable rule: only add/hold material exposure if you have conviction management resolves Masimo litigation and delivers the >100 bps productivity gains (and China/equipment trends stabilize); otherwise trim or avoid until execution certifies.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High profitability
- •Strong FCF
- •Large intangibles
DHR shows strong margins and cash generation with moderate leverage but is priced richly and carries material intangible‑asset risk.
Price Behavior
Key Price Behavior Insights:
- •Downtrend dominant
- •Near-term support
- •Clustered resistance
DHR is in a short-term downtrend over the last month (≈10% drop to $189.35), trading ~6% below its last-month moving average near $201, sitting close to support at $186.26 but capped by resistance in the $209–$211 area.
~10% decline from $211.25 to $189.35 over the last month
Sentiment & News
Key News Insights:
- •Moderate Buy consensus
- •Dividend $0.40
- •Active institutional flows
Danaher secured a Marketbeat "Moderate Buy" consensus amid active institutional rebalancing (more buyers than sellers), increased investor visibility from a TD Cowen presentation, and a confirmed $0.40 quarterly dividend.
The combination of analyst support, dividend confirmation, and heavy but net-positive institutional buying should underpin sentiment and modest upside while leaving room for volatility from large-scale position shifts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings